All articles by Thomas C Novelli
Thomas C Novelli
The need for speed: the US race to improve device regulation
US regulators’ plans to share data, quickening the medical product approval process, have met with a lukewarm reception. Thomas Novelli of the Medical Device Manufacturers Association explains to Rhian Owen why the FDA and CMS’ proposed ‘parallel review’ process is attempting to solve more issues than it can handle.
Save the Innovation Ecosystem
Delays and changes in the device approval process in the US are causing concern among manufacturers and patients. Thomas Novelli of the Medical Device Manufacturers Association asks whether the US can continue to maintain its position as the global leader of innovative medical technologies.
Foreign Affairs: Marketing Medical Devices Overseas
Medical device companies marketing their products in overseas markets face many challenges. Companies should be aware of the new attitude of regulators to actively pursue violators and take steps to ensure good compliance with all aspects of the Foreign Corrupt Practices Act, writes Thomas Novelli, Medical Device Manufacturers Association.
FDA Under Pressure
The FDA’s recall and labelling authority has come under criticism from members of Congress. They are questioning its willingness to approve or clear new medical devices for use in the US. Thomas Novelli of the Medical Device Manufacturers Association, examines the agency’s system and asks is it time for a change?
Stormy Outlook for US Healthcare Industry
Device tax, new regulations and effectiveness research are causing some panic among medical manufacturers in the US. Will the industry be able to weather these changes? Thomas C Novelli of the MDMA investigates.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Innovation Under Siege from Potential Taxes
The implementation of a new device tax under consideration in the US will not only impact patient access and jobs. It will have an adverse effect on innovation, too, as Thomas C Novelli reports.
Change of Face
The medical and pharma industries are waiting to hear the results of the main US review of advertising procedures. With concerns over false information rife, Thomas C Novelli of the MDMA looks at what changes are likely to be proposed and their anticipated consumer and industry effects.
Patents: A New Direction
Copying, counterfeiting and lack of property rights have made the West wary of working with Chinese manufacturers. However, all that could change as legislation becomes more strict and countries work together. Meanwhile, the US and EU are seeing regulatory changes of their own, explains Thomas C Novelli of the MDMA.
Change on the Horizon
How will the election of President Barack Obama in the US affect medical care globally? Thomas C Novelli of the MDMA looks at policy and reforms over issues such as comparative effectiveness, transparency and payment options.
A Costly Global Challenge
Can medical innovation fight back against the pressures of funding and patent protection? Thomas C Novelli of the MDMA investigates the latest regulations to help manufacturers continue producing new technologies.